Alpine Global Management’s Carisma Therapeutics CARM Stock Holding History

Alpine Global Management’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,012	Closed	-$42K	–	254
2019 Q4	$42K	Buy	+2,012	New	+$46.2K	0.01%	398
2015 Q3	–	Sell	-151	Closed	-$9K	–	202
2015 Q2	$9K	Buy	+151	New	+$21.3K	﹤0.01%	999

Other funds holding CARM

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alpine Global Management's CARM Position: Q1 2020 in Review

Alpine Global Management sold out of Carisma Therapeutics (CARM) in Q1 2020, closing a stake of 2,012 shares — an estimated $42K sold.

Alpine Global Management first reported a position in CARM in Q2 2015 and held it in 2 quarters. The position peaked at $42K in Q4 2019. 36 funds tracked by Wall St. Rank hold CARM as of Q1 2020.

Alpine Global Management reported no remaining Carisma Therapeutics position as of Q1 2020 after selling out during the quarter.
Alpine Global Management sold 2,012 Carisma Therapeutics shares in Q1 2020, an estimated $42K.
Alpine Global Management first reported a position in Carisma Therapeutics in Q2 2015 and held it in 2 quarters.
Alpine Global Management's Carisma Therapeutics position peaked at $42K in Q4 2019.
36 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2020.

Based on Alpine Global Management's 13F filing for Q1 2020, filed 9 Apr 2020.